For Black Americans, the battle with Chronic Myeloid Leukemia is marked by unique survival challenges and treatment ...

AML is the most common form of leukemia. The 5-year relative survival rate for AML is 31.9%. Chronic myeloid leukemia (CML) affects mostly adults. About 9,000 new cases of CML are diagnosed ...

Acute myelogenous leukemia (AML) is more common in adults than children and is more likely to affect males than females. Overall, however, it is rare. Chronic myelogenous leukemia (CML ...

Jaypirca is a targeted therapy for CLL and other specific cancers. It is known as a Bruton’s tyrosine kinase inhibitor (BTK inhibitor). BTK is an enzyme that helps certain types of cancer cells ...

Imatinib, a tyrosine kinase inhibitor of Bcr-Abl, is the current first-line therapy for patients with chronic myelogenous leukemia (CML). Despite the effectiveness of imatinib, many patients ...

By Daniella Parra Ascentage Pharma (NASDAQ: AAPG; HKEX) said that its drug Olverembatinib is the first China-approved ...

Synribo (omacetaxine mepesuccinate), for injection to treat adults with chronic phase or accelerated phase chronic myelogenous leukemia (CML) with resistance and / or intolerance to two or more ...